

Remarks

In response to the Restriction Requirement mailed October 18, 2006 in connection with the above-identified patent application. Applicants elect Group I, containing claims 1-112, drawn to compositions. Applicants further elect the species wherein the chimeric oligomeric compound is a gapped oligomeric compound, each of the first type of nucleosides are 2'-OCH₃ modified nucleosides and the second type of nucleosides ribonucleosides. Applicants further elect for the species of internucleoside linkage a mixture of phosphodiester and phosphorothioate internucleoside linkages.

A listing of the claims has been included to clarify the election. Claims 1, 10, 14, 15 and 40 have been amended, claims 11-12, 16-39, 41-109 and 11-118 have been canceled. Claim 1 has been amended to limit the chimeric oligomeric compound to gapped oligomeric compounds. Claim 119 is newly added requiring each internucleoside linkage to be either a phosphodiester or phosphorothioate internucleoside linkage. This claim is fully supported in the examples and also in the specification starting at page 15, paragraph 56. No new matter has been added.

Respectfully submitted,



Robert S. Andrews

Registration No. 44,508

Date: 4-18-07

ISIS Pharmaceuticals, Inc.
1896 Rutherford Rd.
Carlsbad, CA 92008
Telephone: (760) 603-2722
Facsimile: (760) 603-3820